These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20025245)

  • 1. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies.
    Cook JA; Feng B; Fenner KS; Kempshall S; Liu R; Rotter C; Smith DA; Troutman MD; Ullah M; Lee CA
    Mol Pharm; 2010 Apr; 7(2):398-411. PubMed ID: 20025245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.
    Fenner KS; Troutman MD; Kempshall S; Cook JA; Ware JA; Smith DA; Lee CA
    Clin Pharmacol Ther; 2009 Feb; 85(2):173-81. PubMed ID: 18987624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo.
    Poirier A; Cascais AC; Bader U; Portmann R; Brun ME; Walter I; Hillebrecht A; Ullah M; Funk C
    Drug Metab Dispos; 2014 Sep; 42(9):1411-22. PubMed ID: 24939652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
    Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
    Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
    Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
    Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
    Rautio J; Humphreys JE; Webster LO; Balakrishnan A; Keogh JP; Kunta JR; Serabjit-Singh CJ; Polli JW
    Drug Metab Dispos; 2006 May; 34(5):786-92. PubMed ID: 16455806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.
    Keogh JP; Kunta JR
    Eur J Pharm Sci; 2006 Apr; 27(5):543-54. PubMed ID: 16406207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. If the KI is defined by the free energy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer?
    Lumen AA; Acharya P; Polli JW; Ayrton A; Ellens H; Bentz J
    Drug Metab Dispos; 2010 Feb; 38(2):260-9. PubMed ID: 19889884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
    Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
    Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity.
    Nader AM; Foster DR
    J Clin Pharmacol; 2014 Jan; 54(1):3-13. PubMed ID: 24166743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein related drug interactions: clinical importance and a consideration of disease states.
    Lee CA; Cook JA; Reyner EL; Smith DA
    Expert Opin Drug Metab Toxicol; 2010 May; 6(5):603-19. PubMed ID: 20397967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage.
    Sugimoto H; Matsumoto S; Tachibana M; Niwa S; Hirabayashi H; Amano N; Moriwaki T
    J Pharm Sci; 2011 Sep; 100(9):4013-23. PubMed ID: 21678427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays.
    Lee CA; Kalvass JC; Galetin A; Zamek-Gliszczynski MJ
    Clin Pharmacol Ther; 2014 Sep; 96(3):298-301. PubMed ID: 25141954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
    Martin P; Gillen M; Millson D; Oliver S; Brealey C; Elsby R; Baluom M; Lau D; Mant T
    Clin Ther; 2015 Dec; 37(12):2811-22. PubMed ID: 26514315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
    Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ
    Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
    Acharya P; O'Connor MP; Polli JW; Ayrton A; Ellens H; Bentz J
    Drug Metab Dispos; 2008 Feb; 36(2):452-60. PubMed ID: 17967933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.
    Stephens RH; O'Neill CA; Warhurst A; Carlson GL; Rowland M; Warhurst G
    J Pharmacol Exp Ther; 2001 Feb; 296(2):584-91. PubMed ID: 11160647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
    Taub ME; Podila L; Ely D; Almeida I
    Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caco-2 cell methodology and inhibition of the P-glycoprotein transport of digoxin by Aloe vera juice.
    Djuv A; Nilsen OG
    Phytother Res; 2008 Dec; 22(12):1623-8. PubMed ID: 19003953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.
    Ellens H; Deng S; Coleman J; Bentz J; Taub ME; Ragueneau-Majlessi I; Chung SP; Herédi-Szabó K; Neuhoff S; Palm J; Balimane P; Zhang L; Jamei M; Hanna I; O'Connor M; Bednarczyk D; Forsgard M; Chu X; Funk C; Guo A; Hillgren KM; Li L; Pak AY; Perloff ES; Rajaraman G; Salphati L; Taur JS; Weitz D; Wortelboer HM; Xia CQ; Xiao G; Yamagata T; Lee CA
    Drug Metab Dispos; 2013 Jul; 41(7):1367-74. PubMed ID: 23620486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.